Haemonetics Corporation has announced its acquisition of Vivasure Medical, a Galway-based medtech firm, in a deal valued at up to €185 million. This acquisition aims to enhance the scalability of Vivasure’s innovative PerQseal technologies, which focus on minimally invasive vessel closure procedures.
Vivasure Medical, founded in 2009 and located in the Parkmore Business Park, has gained recognition for its PerQseal device. This technology seals blood vessels from the inside, facilitating procedures in cardiology, interventional radiology, and vascular surgery. While the PerQseal and its advanced version, PerQseal Elite, are not yet approved for use in the United States, Vivasure has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration for the PerQseal Elite vascular closure system.
Strategic Development and Future Goals
Following a strategic investment from Haemonetics in 2022, which included an option for acquisition, this complete buyout underscores the commitment to advancing medical technology. In 2023, Vivasure received additional funding of €30 million from Haemonetics aimed at further developing its vessel closure solutions.
Commenting on the acquisition, Andrew Glass, CEO of Vivasure Medical, expressed pride in the advancements made in closure technology and gratitude towards the clinicians who supported the company’s mission. He stated, “Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide.”
Ger Brett, COO and co-founder of Vivasure Medical, also highlighted the contributions of the company’s employees, founders, investors, and government bodies. He noted, “We’re proud to make PerQseal in Ireland and distribute it around the world.”
Market Implications and Clinical Relevance
The acquisition aligns with Haemonetics’ strategy to expand its portfolio in the medical device sector, particularly in areas that enhance patient care through innovative technology. The PerQseal system is designed to improve patient outcomes by providing a less invasive option for vascular closure, which is especially relevant in fields such as cardiology.
As the integration of Vivasure Medical into Haemonetics progresses, stakeholders in the medical community will be watching closely to see how this partnership enhances the availability of advanced medical technologies. The potential for improved clinical outcomes could significantly impact patient care across various medical disciplines.
This acquisition not only marks a significant milestone for both companies but also highlights the growing importance of innovative solutions in the healthcare sector. The future of Vivasure Medical under Haemonetics could lead to expanded access to its technologies, ultimately benefiting patients and healthcare providers alike.
